Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | FAAH | O00519 | 8/20 | 0.42 |
| ▸ | CES1 | P23141 | 5/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28224073 | 0.98 | EPHX1 (0.53) | EPHX1MLYCDGPR84FAAHCES1 | |
| SCHEMBL4172800 | 0.94 | EPHX1 (0.47) | EPHX1MLYCDGPR84FAAHCES1 | |
| SCHEMBL28253440 | 0.86 | EPHX1 (0.41) | EPHX1MLYCDFAAHCES1CES2 | |
| SCHEMBL7045874 | 0.81 | MLYCD (0.57) | EPHX1MLYCDFAAHCES1CES2 | |
| SCHEMBL570466 | 0.80 | EPHX1 (0.49) | EPHX1MLYCDGPR84FAAHCES1 | |
| SCHEMBL5273339 | 0.80 | EPHX1 (0.49) | EPHX1MLYCDGPR84FAAHCES1 | |
| SCHEMBL5270070 | 0.80 | EPHX1 (0.49) | EPHX1MLYCDGPR84FAAHCES1 | |
| SCHEMBL18349792 | 0.79 | EPHX1 (0.47) | EPHX1MLYCDFAAHCES1CES2 | |
| SCHEMBL17972439 | 0.79 | EPHX1 (0.51) | EPHX1MLYCDGPR84FAAHCES1 | |
| SCHEMBL8179038 | 0.77 | NOD1 (0.54) | EPHX1GPR84FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105228451-A | Process for preparing prostacyclin compounds having a thiol linker and a pegylated form | UNITED THERAPEUTICS CORP | 2016-01-06 | — | — | CN | disclosed |
| US-20140187434-A1 | Nucleic Acid Labeling Compounds | AFFYMETRIX, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2014066084-A1 | NUCLEIC ACID MODULATORS OF ALPHA2BETA1 | NOVAMEDICA LIMITED LIABILITY COMPANY (RU) | 2014-05-01 | — | — | WO | disclosed |
| CN-103608042-A | Method for producing PEGylated oligonucleotides | REGADO BIOSCIENCES INC | 2014-02-26 | — | — | CN | disclosed |
| US-8497064-B2 | Nucleic acid labelling compounds | AFFYMETRIX, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120053336-A1 | Nucleic Acid Labelling Compounds | AFFYMETRIX, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-8076072-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8026057-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110082289-A1 | Nucleic Acid Labeling Compounds | AFFYMETRIC, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7468243-B2 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | AFFYMETRIX, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080287667-A1 | Nucleic Acid Labeling Compounds | AFFYMETRIX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1385829-A4 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX INC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1385829-A2 | NUCLEIC ACID LABELING COMPOUNDS | Affymetrix, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20020182625-A1 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | AFFYMETRIX, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002072779-A2 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082289-A1 | Nucleic Acid Labeling Compounds | RNGTT, DUT, FBL | EPHX1 3043/4885MLYCD 540/4885GPR84 4031/4885 |
| US-20080287667-A1 | Nucleic Acid Labeling Compounds | RNGTT, DUT, FBL | EPHX1 2239/4885MLYCD 472/4885GPR84 3491/4885 |
| US-20120053336-A1 | Nucleic Acid Labelling Compounds | RNGTT, DUT, FBL | EPHX1 2975/4885MLYCD 475/4885GPR84 3852/4885 |
| US-20020182625-A1 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | RNGTT, POLM, RNMT | EPHX1 3354/4885MLYCD 176/4885GPR84 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.